Skip to content

DK Nano-Culotte Stenting For Coronary Bifurcation Lesion

A Novel Coronary Bifurcation Stenting Technique With Minimal Protrusion: Double Kissing Nano-Culotte Stenting

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05406284
Enrollment
43
Registered
2022-06-06
Start date
2024-07-01
Completion date
2026-07-30
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

coronary bifurcation lesion, DK nano-culotte stenting

Brief summary

True coronary bifurcation lesions are still great of interest due to their complex anatomy, uncertainty of optimal stenting strategy and increased adverse cardiovascular outcomes. Provisional stenting is recommended in patients with non-complex coronary lesions while 2-stent strategies should be considered in complex coronary bifurcation lesions. However, optimal 2-stent strategy is still controversial. Double kissing (DK) crush stenting is the prominent technique in true bifurcation lesion, especially in patients with left main coronary artery disease. DK mini-culotte stenting, increasing use in clinical practice, has become popular over DK crush stenting. It was demonstrated in a bench test that stent malapposition was lower in the DK mini-culotte stenting compared to the DK crush technique. Thus, DK mini-culotte stenting may be preferred over DK crush stenting in complex true coronary bifurcation lesion. On the other hand, it was demonstrated in previous studies, less than minimal protrusion (generally called as nano protrusion) had better clinical outcomes. Kawasaki et al was first demonstrated the minimal (nano) protrusion of culotte stenting technique. Then, Toth et al revealed a novel modified culotte stenting technique named single string culotte. There was no major adverse cardiac events (MACE) in patients underwent single string stenting technique with a median follow-up period of 6±4 months. Unsurprisingly there was no MACE occurred in patients who underwent Szabo 2-stent technique. In the light of foregoing data, the least possible amount of protrusion is known to have the best results. In addition to this, double kissing balloon dilatation with culotte stenting technique seems to have better results than other stenting techniques. In our study, we aimed to evaluate the angiographic and clinical results of a novel DK Nano-Culotte stenting in coronary bifurcation lesion.

Interventions

PROCEDUREdouble kissing nano culotte stenting

patients with true coronary bifurcation lesion treating with double kissing nano culotte stunting technique

Sponsors

Istanbul Mehmet Akif Ersoy Educational and Training Hospital
Lead SponsorOTHER_GOV
Turkish Society of Cardiology
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years

Inclusion criteria

* Patients with de novo true bifurcation lesion (Medina classification 1,1,1 or 0,1,1 or 1,0,1) * The main vessel diameter is least 2.5 mm and the side branch diameter is at least 2.25 mm

Exclusion criteria

* Patients presenting with ST segment elevation myocardial infarction, cardiogenic shock and Killip class III-IV heart failure * Patients with a history of coronary artery bypass grafting surgery * Patients with a chronic total occlusion in the bifurcation area * Lesions with severe calcification that needs additional intervention such as atherectomy * Patients who are not suitable to use long term dual antiplatelet therapy and patients not participating in clinical follow-up * Patients with hematological disorders, malignancy, end stage renal (GFR\<30 ml/min) and hepatic failure * Patients with active bleeding * Pregnant women * Patients with life-expectancy \< 1 year * Patients treated with small open cell stent platforms

Design outcomes

Primary

MeasureTime frameDescription
MACE (major adverse cardiovascular events)12 monthstarget lesion revascularization, myocardial infarction or cardiac death

Secondary

MeasureTime frameDescription
MACCE (major adverse cerebral and cardiovascular events)6, 12 monthsall cause death, myocardial infarction, target vessel revascularization, in-stent thrombosis/restenosis or stroke
target lesion failure6, 12 monthstarget lesion revascularization, myocardial infarction, cardiac death

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 11, 2026